Synutra infant formula receives Chinese approval
The safety of the products has been confirmed by Government of Duchang County in Jiangxi Province, China. Incidents of a male infant death and illness of his twin

The safety of the products has been confirmed by Government of Duchang County in Jiangxi Province, China. Incidents of a male infant death and illness of his twin

Reteplase is a recombinant protein and the active ingredient in the medicinal product Rapilysin, used for thrombolytic treatment of myocardial infarction. Except in US and Canada, Actavis owns

The alliance also includes Brigham and Women’s Hospital. The deal will focus on kidney biology, physiology and disease along with a set of tools to identify, validate and

The product is said to be in compliance with the Guidelines for Health Supplements. CereNate DHA is made from an unblended GRAS registered algae oil omega-3 in an

The joint venture, Life Technologies DaAn Diagnostics is expected to contribute to the early diagnosis of oncology, infectious diseases and genetic diseases. Life Technologies DaAn Diagnostics will develop

Dishman Netherlands plans to produce, market, and sell Vitamin D3 for pharmaceutical, food markets as well as for the animal feed, from their new facility in India which

Carbogen Amcis’ portfolio of development and manufacturing services will undergo an expansion with the addition of formulation, lyophilization services and sterile GMP capabilities. The services are believed to

The company is said to be developing NurOwn to treat ALS which is a progressive neurodegenerative disease, Reuters reported. The researchers transplanted the patients with their own stem

The study was named ‘Infusing Chilled Saline Through the Intraosseous Route is Equivalent to Infusion Through the Intravenous Route in Reducing the Core Temperature in Swine.’ It investigated

Cellectis manufactures DNA scissors called nucleases that can cut precise DNA sequences allowing for the creation of a wide range of specific tools to modify a target gene.